

ANTIGENICS INC /DE/  
Form 8-K  
July 15, 2009

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of**  
**the Securities Exchange Act of 1934**

July 9, 2009

Date of Report (Date of earliest event reported)

**ANTIGENICS INC.**

(Exact name of registrant as specified in its charter)

**DELAWARE**  
(State or other jurisdiction)

**000-29089**  
(Commission)

**06-1562417**  
(IRS Employer)

Edgar Filing: ANTIGENICS INC /DE/ - Form 8-K

(State of incorporation)

(File Number)

(Identification No.)

**3 Forbes Road**

**Lexington, MA**  
(Address of principal executive offices)

**781-674-4400**

**02421**  
(Zip Code)

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 1.01 Entry into a material definitive agreement**

On July 9, 2009, Antigenics Inc. ( Antigenics ) executed a Supply Agreement (the Agreement ) with ISSI Strategy, LLC ( ISSI ) for the sale and supply of Antigenics autologous cancer vaccine, Oncophage® to ISSI for sale in the Russian Federation. The term of the Agreement expires on the third anniversary of the Agreement or upon the termination of a to be executed distribution agreement related to the sale and distribution of Oncophage® in Russia by ISSI, unless earlier terminated by the parties in accordance with the terms of the Agreement.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ANTIGENICS INC.**

Date: July 15, 2009

By: /s/ Garo H. Armen  
Garo H. Armen  
Chairman and CEO